Welcome to our dedicated page for Altamira Therapeutics news (Ticker: CYTOF), a resource for investors and traders seeking the latest updates and insights on Altamira Therapeutics stock.
Altamira Therapeutics Ltd. develops and supplies peptide-based nanoparticle technologies for nucleic acid delivery to targets beyond the liver. Its xPhore platform is positioned for siRNA, mRNA, circular RNA and DNA payloads and is made available to pharmaceutical and biotechnology companies through out-licensing.
Company news centers on platform applications such as SemaPhore, CycloPhore and GenePhore, scientific publications, patent activity, partner development projects and financial results. Updates also cover the preclinical siRNA programs AM-401 for KRAS-driven cancer and AM-411 for rheumatoid arthritis, as well as Altamira Medica AG's Bentrio nasal spray for allergic rhinitis, including medical-device certifications, market approvals and distribution-related developments.
Altamira Therapeutics (OTCID:CYTOF) announced publication of a peer-reviewed review in npj Biomedical Innovations on April 13, 2026, highlighting the potential of RNA therapeutics plus advanced delivery platforms to enable disease-modifying treatments for osteoarthritis.
The paper emphasizes RNA precision, delivery challenges to joints versus liver, and cites Altamira's xPhore nanoparticle platform tested in animal models for targeting inflamed joints.
Altamira Therapeutics (OTCID:CYTOF) reported full year 2025 results and a business update. The company advanced its xPhore nucleic acid delivery platform (added GenePhore for DNA), completed a legal carve-out of ATAG, raised $0.7M in convertible loans for ATAG, and progressed a planned spin-off.
Financials: 2025 net loss narrowed to $3.0M from $8.5M, operating loss fell to $4.4M, cash was $464, shareholders' equity was $3.0M. Medica achieved EU MDR clearance and China approval and earned a $1M milestone.
Altamira Therapeutics (OTCID:CYTOF) will release its annual report and financial statements for the fiscal year ended December 31, 2025 on March 31, 2026 at 9:00 AM EDT. The release is expected to include audited financial statements and related disclosures.
Altamira Therapeutics (OTCID:CYTOF) said its associate Altamira Medica received a Japan Patent Office notice of allowance for a patent covering Bentrio® nasal spray.
Bentrio is described as a drug‑free, preservative‑free medical device, approved or cleared in several countries for prophylaxis and treatment of allergic rhinitis, with clinical data supporting safety and efficacy.
Altamira Therapeutics (OTCID:CYTOF) will present at the 5th mRNA-Based Therapeutics Summit Europe on January 28-29, 2026 in Berlin. Covadonga Pañeda, Ph.D., Chief Operating Officer, will present "CycloPhore & SemaPhore enabling next-generation delivery solutions for circular RNA & mRNA therapeutics." The company described differences between linear mRNA (faster onset, controllable, transient expression) and circular RNA (longer or enhanced expression, reduced dosing) and positioned its CycloPhore and SemaPhore platforms as delivery technologies designed to maximize each modality's advantages for acute and chronic indications.
Altamira Therapeutics (OTCID:CYTOF) announced that associate Altamira Medica received NMPA marketing approval in Mainland China for Bentrio® nasal spray in allergic rhinitis on December 19, 2025. The clearance permits partner Nuance Pharma to market and distribute Bentrio across Mainland China. Epidemiological estimates cited in the announcement put the potential addressable population at ~200 million people with allergic rhinitis. The company highlighted Bentrio's preservative-free formulation and a triple mode of action, and said trials showed efficacy and good tolerability. The announcement frames the approval as a commercial milestone and the start of a China launch by Nuance Pharma.
Altamira Therapeutics (OTCQB:CYTOF) announced on November 20, 2025 that associate Altamira Medica obtained EU Medical Device Regulation (MDR) certification for Bentrio nasal spray. The certification confirms conformity with the EU's stricter safety, performance and quality requirements for medical devices and is a prerequisite for legally commercializing Bentrio in EU member states.
The announcement notes Bentrio was previously launched under the MDD as a Class I device in 2021 and was up‑classified to Class IIa under MDR, which required clinical trials, independent Notified Body certification and substantial investments by Medica. The company says MDR status also supports regulatory filings outside the EU and aids the product's international growth strategy.
Altamira Therapeutics (OTCQB:CYTOF) announced on November 3, 2025 that its peptide‑based nanoparticle platform xPhore successfully delivered DNA molecules in vitro, producing efficient cell transfection and reliable protein expression.
Altamira will offer the DNA delivery capability under the GenePhore label, complementing existing offerings for short RNA (OligoPhore), linear mRNA (SemaPhore) and circular RNA (CycloPhore).
The company said GenePhore could support applications including DNA vaccines, gene editing, and protein replacement therapies. The announcement cites independent research estimating the global gene delivery technologies market at $5.35 billion in 2024 and projecting growth to $22.8 billion by 2034.
Altamira Therapeutics (OTCQB:CYTOF) reported its first half 2025 financial results and business updates, highlighting progress in its RNA delivery technology business. The company's operating loss decreased by 32.9% to $2.6 million, while net loss reduced by 64.6% to $1.5 million compared to H1 2024.
Key developments include securing two new collaboration partners for evaluating xPhore platform technology, including CycloPhore for circular RNA delivery. The company is advancing plans for a partial spin-off of its RNA delivery business through its Swiss subsidiary ATAG, while reducing operating expenses. Cash and cash equivalents stood at $4,000 as of June 30, 2025, down from $1.0 million at year-end 2024.
Progress was also reported in legacy assets, including Bentrio® nasal spray's transition to Class IIa medical device status in the EU and expanded patent coverage for AM-125 in over 50 countries.
[ "Operating loss decreased 32.9% to $2.6 million in H1 2025", "Net loss reduced significantly by 64.6% to $1.5 million", "Cash used in operations decreased by 56.8% to $1.4 million", "Secured two new RNA delivery collaboration partners in 2025", "Expanded patent coverage for AM-125 to over 50 countries" ]Altamira Therapeutics (OTCQB:CYTOF), focused on RNA delivery technology development beyond liver applications, has scheduled its First Half 2025 Financial Results and Business Update Call for August 29, 2025, at 8:00 am ET.
The conference call will feature prepared remarks from Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda. The event will be accessible via toll-free and international dial-in numbers, with a webcast option available. A replay will be accessible 30 minutes after the live event through September 12, 2025.